Melphalan

"Melphalan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.

Descriptor ID	D008558
MeSH Number(s)	D02.455.526.728.650.594 D12.125.072.050.685.500
Concept/Terms	Melphalan Melphalan L-PAM Phenylalanine Mustard Mustard, Phenylalanine 4-(Bis(2-chloroethyl)amino)phenylalanine Medphalan Medphalan Sarkolysin Sarkolysin Sarcolysine Merphalan Alkeran Alkeran

Below are MeSH descriptors whose meaning is more general than "Melphalan".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Halogenated [D02.455.526]
Mustard Compounds [D02.455.526.728]
Nitrogen Mustard Compounds [D02.455.526.728.650]
Melphalan [D02.455.526.728.650.594]
Amino Acids, Peptides, and Proteins [D12]
Amino Acids [D12.125]
Amino Acids, Cyclic [D12.125.072]
Amino Acids, Aromatic [D12.125.072.050]
Phenylalanine [D12.125.072.050.685]
Melphalan [D12.125.072.050.685.500]

Below are MeSH descriptors whose meaning is related to "Melphalan".

Below are MeSH descriptors whose meaning is more specific than "Melphalan".

Melphalan
Peptichemio

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Melphalan" by people in this website by year, and whether "Melphalan" was a major or minor topic of these publications.

Bar chart showing 41 publications over 17 distinct years, with a maximum of 6 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	2	1	3
2005	1	1	2
2007	0	1	1
2008	1	0	1
2009	0	2	2
2011	3	3	6
2012	2	0	2
2013	2	0	2
2014	2	2	4
2015	0	2	2
2016	2	3	5
2017	1	1	2
2018	1	1	2
2019	1	3	4
2020	1	0	1
2021	0	1	1
2024	1	0	1

Below are the most recent publications written about "Melphalan" by people in Profiles.

Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study. Ann Surg Oncol. 2024 Aug; 31(8):5340-5351.

View in: PubMed
Shields CL, Dockery PW, Yaghy A, Duffner ER, Levin HJ, Taylor OS, Sajjadi Z, Lally SE, Shields JA, Rosenwasser R, Tjoumakaris S, Jabbour P. Intra-arterial chemotherapy for retinoblastoma in 341 consecutive eyes (1,292 infusions): comparative analysis of outcomes based on patient age, race, and sex. J AAPOS. 2021 06; 25(3):150.e1-150.e9.

View in: PubMed
Sweid A, Hammoud B, Weinberg JH, Texakalidis P, Xu V, Shivashankar K, Baldassari MP, Das S, Ramesh S, Tjoumakaris S, Shields CL, Ancona-Lezama D, Lim LS, Dalvin LA, Jabbour P. Intra-Arterial Chemotherapy for Retinoblastoma in Infants =10 kg: 74 Treated Eyes with 222 IAC Sessions. AJNR Am J Neuroradiol. 2020 07; 41(7):1286-1292.

View in: PubMed
Ancona-Lezama D, Dalvin LA, Lucio-Alvarez JA, Jabbour P, Shields CL. OPHTHALMIC VASCULAR EVENTS AFTER INTRA-ARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA: Real-World Comparison Between Primary and Secondary Treatments. Retina. 2019 Dec; 39(12):2264-2272.

View in: PubMed
Selzer EB, Welch RJ, Jabbour P, Leahey AM, Shields CL. Management of retinoblastoma in older children (>5 years) using intra-arterial chemotherapy: Comparison of outcomes to prechemotherapy and intravenous chemotherapy eras. Indian J Ophthalmol. 2019 12; 67(12):2005-2011.

View in: PubMed
Ravindran K, Dalvin LA, Pulido JS, Brinjikji W. Intra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis. J Neurointerv Surg. 2019 Dec; 11(12):1266-1272.

View in: PubMed
Camp DA, Lally SE, Shields CL. Heterochromia following intravitreal chemotherapy in two cases. J AAPOS. 2019 08; 23(4):241-243.

View in: PubMed
Dalvin LA, Ancona-Lezama D, Lucio-Alvarez JA, Masoomian B, Jabbour P, Shields CL. Ophthalmic Vascular Events after Primary Unilateral Intra-arterial Chemotherapy for Retinoblastoma in Early and Recent Eras. Ophthalmology. 2018 11; 125(11):1803-1811.

View in: PubMed
Hari P, Reece DE, Randhawa J, Flomenberg N, Howard DS, Badros AZ, Rapoport AP, Meisenberg BR, Filicko-Ohara J, Phillips GL, Vesole DH. Final outcomes of escalated melphalan 280?mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival. Bone Marrow Transplant. 2019 02; 54(2):293-299.

View in: PubMed
Ozuah NW, Dahmoush HM, Grant FD, Lehmann LE, LaCasce AS, Billett AL, Margossian SP. Pretransplant functional imaging and outcome in pediatric patients with relapsed/refractory Hodgkin lymphoma undergoing autologous transplantation. Pediatr Blood Cancer. 2018 Jan; 65(1).

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement